THYROCARE
Thyrocare Technologies Limited
Each stock's 10,000-path forecast, rendered as light.
Thyrocare Technologies Limited (THYROCARE) Stock Analysis & Case Study
Is THYROCARE a good buy? The data-driven verdict.
Thyrocare Technologies Limited (THYROCARE) trades at ₹603,on the numbers it mixed signals, a Downstox Snapshot Score of 52/100.
On the numbers, Thyrocare Technologies Limited (THYROCARE) mixed signals, a Downstox Snapshot Score of 52/100, weighing expensive at 53.1× earnings, ROE of 28.4%, a 51% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
THYROCARE fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How THYROCARE ranks against the 2,373 companies in our screener
- THYROCARE's market cap of 9,602 Cr ranks in the 75th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- THYROCARE's book value of ₹37 ranks in the 27th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- THYROCARE's promoter holding of 60.9% ranks in the 53rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- THYROCARE's 3-year profit (PAT) growth of 36.0% ranks in the 75th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- THYROCARE's 3-year revenue growth of 16.0% ranks in the 65th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- THYROCARE's debt-to-equity ratio of 0.09x is lower than 79% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is THYROCARE overvalued? THYROCARE P/E vs peers
THYROCARE trades at 53.1× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
THYROCARE share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of THYROCARE history (12%/yr drift, 40%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| THYROCARE 2027 | ₹369 | ₹610 | ₹1,008 | +1% |
| THYROCARE 2028 | ₹295 | ₹617 | ₹1,291 | +2% |
| THYROCARE 2029 | ₹254 | ₹624 | ₹1,533 | +3% |
| THYROCARE 2030 | ₹225 | ₹631 | ₹1,769 | +5% |
| THYROCARE 2031 | ₹202 | ₹638 | ₹2,014 | +6% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability THYROCARE goes up, or doubles?
The bull case for THYROCARE
- THYROCARE's return on equity of 28.4% ranks in the 93rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- THYROCARE's return on capital employed of 35.4% ranks in the top 5% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,533.
The bear case & risks
- THYROCARE's P/E of 53.1x is lower than 25% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 16.4× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹254.
THYROCARE volatility & expected range, how bumpy is the ride?
Over the last 9.8 years THYROCARE compounded at 12%/year with annualized volatility of 40%. That volatility implies a 1-year 80% range of ₹369-₹1,008, the honest backbone behind any single price target.
THYROCARE price forecast, the full 60-month probability fan
THYROCARE price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds THYROCARE hits common targets within the simulated horizon?
Full multi-horizon detail on the THYROCARE price target & forecast page.
THYROCARE Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. THYROCARE scores 6/8, mixed financial health.
THYROCARE MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy THYROCARE with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| ZerodhaCHEAPEST | 33.83% | 3.0× |
| Groww | 33.98% | 2.9× |
| Dhan | 89.00% | 1.1× |
| Kotak Neo | 40.00% | 2.5× |
| Paytm Money | 75.00% | 1.3× |
| Pocketful | 33.94% | 2.9× |
| Fyers | 90.91% | 1.1× |
| Anand Rathi | 75.00% | 1.3× |
| Bajaj Broking | 89.00% | 1.1× |
| Share India | 33.97% | 2.9× |
Compare every broker on the THYROCARE MTF page.
About Thyrocare Technologies Limited: sector, index & market-cap context
Thyrocare Technologies Limited (THYROCARE) is a small-cap NSE-listed company, with a market capitalisation of ₹9,602 Cr. See more stocks on our screener.
How the THYROCARE Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Thyrocare Technologies Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
THYROCARE analysis, FAQs
Is Thyrocare Technologies Limited (THYROCARE) a good buy?
On the numbers, Thyrocare Technologies Limited (THYROCARE) mixed signals, a Downstox Snapshot Score of 52/100, weighing expensive at 53.1× earnings, ROE of 28.4%, a 51% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is THYROCARE overvalued or undervalued?
THYROCARE trades at 53.1× earnings, expensive versus the ~22× long-run Nifty average.
What is the THYROCARE share price target for 2031?
THYROCARE's probability-weighted 2031 median target is ₹638, with an 80% range of ₹202-₹2,014 (10,000-path Monte-Carlo).
What is the probability THYROCARE doubles in 5 years?
The modelled probability of THYROCARE reaching ₹1,207 (2×) within 5 years is 24%.
What is the bull case for THYROCARE?
THYROCARE's return on equity of 28.4% ranks in the 93rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. THYROCARE's return on capital employed of 35.4% ranks in the top 5% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in THYROCARE?
THYROCARE's P/E of 53.1x is lower than 25% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 16.4× price-to-book means most of the value is intangible/expectations, not assets on the books.